Aliases & Classifications for Bone Disease

MalaCards integrated aliases for Bone Disease:

Name: Bone Disease 12 15 17
Bone Diseases 56 44 45 74
Disorder of Skeletal System 74
Skeletal Disorder 56
Skeletal Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080001
MeSH 45 D001847
SNOMED-CT 69 76069003
ICD10 34 M89 M89.8 M89.9

Summaries for Bone Disease

MedlinePlus : 44 Your bones help you move, give you shape and support your body. They are living tissues that rebuild constantly throughout your life. During childhood and your teens, your body adds new bone faster than it removes old bone. After about age 20, you can lose bone faster than you make bone. To have strong bones when you are young, and to prevent bone loss when you are older, you need to get enough calcium, vitamin D, and exercise. You should also avoid smoking and drinking too much alcohol. Bone diseases can make bones easy to break. Different kinds of bone problems include Low bone density and osteoporosis, which make your bones weak and more likely to break Osteogenesis imperfecta makes your bones brittle Paget's disease of bone makes them weak Bones can also develop cancer and infections Other bone diseases, which are caused by poor nutrition, genetics, or problems with the rate of bone growth or rebuilding NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Bone Disease, also known as bone diseases, is related to ischemic bone disease and osteopetrosis, and has symptoms including back pain, bone pain and sciatica. An important gene associated with Bone Disease is DANCR (Differentiation Antagonizing Non-Protein Coding RNA), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and Osteoclast differentiation. The drugs AT-101 and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotypes are cellular and growth/size/body region

Disease Ontology : 12 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.

Wikipedia : 77 Bone disease refers to the medical conditions which affect the... more...

Related Diseases for Bone Disease

Diseases related to Bone Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 420, show less)
# Related Disease Score Top Affiliating Genes
1 ischemic bone disease 33.8 ACP5 BGLAP PTH RUNX2 SOST TNFRSF11A
2 osteopetrosis 33.5 CTSK TNFRSF11A TNFSF11
3 paget disease of bone 5, juvenile-onset 33.1 CALCA TNFRSF11A TNFRSF11B TNFSF11
4 osteitis fibrosa 32.8 B2M BGLAP CALCA PTH
5 paget's disease of bone 32.7 B2M BGLAP CALCA TNFRSF11A TNFRSF11B TNFSF11
6 hypophosphatasia 32.2 ALPL ALPP RUNX2
7 arthropathy 32.2 B2M TNFRSF11B TNFSF11
8 bone inflammation disease 32.2 ACP5 BGLAP CTSK TNFRSF11B TNFSF11
9 osteonecrosis 32.1 ACP5 BGLAP PTH RUNX2 TNFRSF11B TNFSF11
10 primary hyperparathyroidism 32.1 ALPP BGLAP CALCA FGF23 PTH VDR
11 chronic kidney failure 32.0 B2M BGLAP CALCA FGF23 PTH TNFRSF11B
12 multicentric carpotarsal osteolysis syndrome 31.9 BGLAP CTSK TNFRSF11A TNFRSF11B TNFSF11
13 renal osteodystrophy 31.9 BGLAP CALCA FGF23 PTH SOST TNFRSF11B
14 osteopetrosis, autosomal recessive 7 31.8 TNFRSF11A TNFSF11
15 cleidocranial dysplasia 31.7 ALPL BGLAP RUNX2
16 hypophosphatasia, adult 31.7 ALPL BGLAP CALCA PTH
17 osteopetrosis, autosomal dominant 2 31.6 ACP5 BGLAP CTSK SOST TNFSF11
18 enchondromatosis, multiple, ollier type 31.4 ACP5 EXT1 EXT2
19 myeloma, multiple 31.3 B2M DKK1 FGFR3 TNFRSF11B TNFSF11
20 hyperparathyroidism 30.9 ACP5 BGLAP CALCA FGF23 PTH TNFRSF11B
21 kidney disease 30.7 B2M FGF23 PTH TNFRSF11B VDR
22 rickets 30.6 ALPL BGLAP FGF23 PTH VDR
23 uremia 30.6 B2M PTH TNFRSF11B VDR
24 osteomalacia 30.6 ALPL BGLAP CALCA FGF23 PTH VDR
25 bone remodeling disease 30.5 ACP5 BGLAP CALCA CTSK EXT1 EXT2
26 hypophosphatemia 30.5 BGLAP FGF23 PTH
27 parathyroid adenoma 30.4 BGLAP CALCA PTH VDR
28 idiopathic hypercalciuria 30.4 BGLAP TNFSF11 VDR
29 rheumatoid arthritis 30.4 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
30 endosteal hyperostosis, autosomal dominant 30.3 CTSK TNFRSF11B TNFSF11
31 osteomyelitis 30.2 ACP5 CTSK TNFSF11
32 fibrogenesis imperfecta ossium 30.2 CALCA PTH TNFRSF11B
33 hypoparathyroidism 30.2 ALPP BGLAP FGF23 PTH
34 bone resorption disease 30.2 ACP5 BGLAP CALCA CTSK DKK1 PTH
35 monoclonal gammopathy of uncertain significance 30.2 B2M DKK1 FGFR3
36 fibrous dysplasia 30.1 BGLAP CALCA FGF23
37 hyperostosis 30.1 FGF23 SOST TNFRSF11B
38 osteoporosis 30.1 ACP5 ALPL ALPP BGLAP CALCA CTSK
39 hyperphosphatemia 30.0 FGF23 PTH RUNX2 VDR
40 giant cell tumor 29.8 BGLAP CALCA CTSK TNFRSF11A TNFRSF11B TNFSF11
41 glucocorticoid-induced osteoporosis 29.7 ACP5 BGLAP CALCA DKK1 PTH RUNX2
42 polycystic bone disease 12.2
43 hypophosphatemic bone disease 12.1
44 brittle bone disorder 11.9
45 gorham's disease 11.8
46 col1a1/2-related osteogenesis imperfecta 11.3
47 cystic angiomatosis of bone, diffuse 11.2
48 hajdu-cheney syndrome 11.1
49 diaphanospondylodysostosis 11.1
50 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1 11.1
51 odontochondrodysplasia 11.0
52 bent bone dysplasia syndrome 11.0
53 end stage renal failure 11.0
54 osteonecrosis of the jaw 11.0
55 paget disease of bone 3 10.9
56 hypophosphatasia, infantile 10.9
57 premature ovarian failure 1 10.9
58 dysbaric osteonecrosis 10.9
59 acrocapitofemoral dysplasia 10.9
60 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 10.9
61 thanatophoric dysplasia, type i 10.9
62 mesomelic dysplasia, kantaputra type 10.8
63 lateral meningocele syndrome 10.8
64 metatropic dysplasia 10.8
65 hyperparathyroidism, transient neonatal 10.7
66 basilar impression, primary 10.7
67 kyphomelic dysplasia 10.7
68 geleophysic dysplasia 3 10.7
69 anemia, congenital dyserythropoietic, type iii 10.6
70 brachyolmia type 3 10.6
71 klippel-feil syndrome 1, autosomal dominant 10.6
72 cleidorhizomelic syndrome 10.6
73 craniometaphyseal dysplasia, autosomal dominant 10.6
74 epiphyseal dysplasia, multiple, 1 10.6
75 exostoses, multiple, type i 10.6
76 exostoses, multiple, type ii 10.6
77 spondyloepiphyseal dysplasia with congenital joint dislocations 10.6
78 chromosome 8q22.1 duplication syndrome 10.6
79 metachondromatosis 10.6
80 metaphyseal chondrodysplasia, schmid type 10.6
81 kniest dysplasia 10.6
82 scheuermann disease 10.6
83 spondyloepiphyseal dysplasia congenita 10.6
84 chondrodysplasia, grebe type 10.6
85 klippel-feil syndrome 2, autosomal recessive 10.6
86 mucopolysaccharidosis, type iva 10.6
87 osteopetrosis, autosomal recessive 1 10.6
88 osteopetrosis, autosomal recessive 2 10.6
89 osteopetrosis, autosomal recessive 5 10.6
90 osteopetrosis, autosomal recessive 3 10.6
91 spondylocostal dysostosis 1, autosomal recessive 10.6
92 spondyloepiphyseal dysplasia tarda, x-linked 10.6
93 epiphyseal dysplasia, multiple, 2 10.6
94 achondrogenesis, type ib 10.6
95 spondylospinal thoracic dysostosis 10.6
96 acromesomelic dysplasia, maroteaux type 10.6
97 intervertebral disc disease 10.6
98 osteopetrosis, autosomal dominant 1 10.6
99 acromesomelic dysplasia, demirhan type 10.6
100 osteopetrosis, autosomal recessive 4 10.6
101 osteopetrosis, autosomal recessive 6 10.6
102 klippel-feil syndrome 3, autosomal dominant 10.6
103 klippel-feil syndrome 4, autosomal recessive, with nemaline myopathy and facial dysmorphism 10.6
104 spondyloepimetaphyseal dysplasia, faden-alkuraya type 10.6
105 spondyloepimetaphyseal dysplasia, di rocco type 10.6
106 spondyloepimetaphyseal dysplasia, krakow type 10.6
107 acromesomelic dysplasia 10.6
108 juvenile primary osteoporosis 10.6
109 polyarticular onset juvenile idiopathic arthritis 10.6 TNFRSF11A TNFRSF11B TNFSF11
110 coxa vara 10.6
111 ischiocoxopodopatellar syndrome 10.6
112 parastremmatic dwarfism 10.6
113 spondyloepimetaphyseal dysplasia, strudwick type 10.6
114 spondylometaphyseal dysplasia, kozlowski type 10.6
115 multiple synostoses syndrome 1 10.6
116 hypophosphatemic rickets, autosomal dominant 10.6
117 gaucher disease, type i 10.6
118 hypophosphatasia, childhood 10.6
119 opsismodysplasia 10.6
120 spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures 10.6
121 spondylometaepiphyseal dysplasia, short limb-hand type 10.6
122 spondyloepimetaphyseal dysplasia, x-linked 10.6
123 paget disease of bone 2, early-onset 10.6
124 spondyloepimetaphyseal dysplasia, missouri type 10.6
125 spondyloepimetaphyseal dysplasia with joint laxity, type 2 10.6
126 spondyloepimetaphyseal dysplasia, matrilin-3 related 10.6
127 multiple synostoses syndrome 2 10.6
128 spondyloepimetaphyseal dysplasia, aggrecan type 10.6
129 multiple synostoses syndrome 3 10.6
130 catel-manzke syndrome 10.6
131 multiple synostoses syndrome 4 10.6
132 osteochondritis dissecans 10.6
133 osteochondrosis 10.6
134 spinal stenosis 10.6
135 cole-carpenter syndrome 10.6
136 bone development disease 10.6
137 bone structure disease 10.6
138 gastroparesis 10.6
139 melorheostosis 10.6
140 crystal arthropathies 10.6
141 hemophilic arthropathy 10.6 TNFRSF11A TNFRSF11B TNFSF11
142 familial expansile osteolysis 10.6 TNFRSF11A TNFRSF11B TNFSF11
143 aneurysmal bone cysts 10.6 CALCA TNFRSF11A TNFSF11
144 axial osteomalacia 10.6 BGLAP PTH
145 periapical periodontitis 10.5 ACP5 TNFRSF11A TNFRSF11B TNFSF11
146 multicentric reticulohistiocytosis 10.5 TNFRSF11B TNFSF11
147 extraskeletal chondroma 10.5 BGLAP PTH
148 breast leiomyosarcoma 10.5 TNFRSF11A TNFSF11
149 kummell's disease 10.5 DKK1 SOST TNFRSF11B TNFSF11
150 hypercalcemia, infantile, 1 10.5 CALCA PTH VDR
151 periodontitis, chronic 10.5 TNFRSF11B TNFSF11
152 bone giant cell tumor 10.5 ACP5 CALCA CTSK TNFSF11
153 chronic apical periodontitis 10.5 TNFRSF11B TNFSF11
154 ankylosis 10.5 BGLAP RUNX2 TNFRSF11B
155 osseous heteroplasia, progressive 10.5 ALPP BGLAP RUNX2
156 villonodular synovitis 10.5 ACP5 TNFSF11
157 hypervitaminosis d 10.5 FGF23 PTH VDR
158 calciphylaxis 10.5 FGF23 PTH VDR
159 aortic valve disease 2 10.5 RUNX2 TNFRSF11B TNFSF11
160 tooth resorption 10.5 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
161 phosphorus metabolism disease 10.5 FGF23 PTH VDR
162 osteogenesis imperfecta, type i 10.5 BGLAP FGFR3 TNFRSF11B
163 periodontitis 10.5 BGLAP CTSK RUNX2 TNFRSF11B TNFSF11
164 hypercementosis 10.5 ACP5 CTSK SOST TNFRSF11A
165 mineral metabolism disease 10.5 CALCA FGF23 PTH VDR
166 hypocalcemia, autosomal dominant 1 10.5 CALCA FGF23 PTH VDR
167 cloacogenic carcinoma 10.5 B2M CALCA PTH
168 impaired renal function disease 10.5 BGLAP FGF23 PTH SOST
169 osteoporosis, juvenile 10.5 BGLAP CALCA DKK1 PTH SOST
170 trichorhinophalangeal syndrome, type i 10.5 EXT1 RUNX2 TNFRSF11B
171 metaphyseal chondrodysplasia, jansen type 10.5 CALCA FGF23 FGFR3 PTH
172 pfeiffer syndrome 10.5 ALPL BGLAP FGFR3 RUNX2
173 giant cell reparative granuloma 10.4 CALCA TNFRSF11A
174 periodontal disease 10.4 TNFRSF11A TNFRSF11B TNFSF11
175 sclerosteosis 10.4 RUNX2 SOST VDR
176 parathyroid gland disease 10.4 BGLAP CALCA FGF23 PTH VDR
177 root resorption 10.4 CALCA CTSK RUNX2 TNFRSF11A TNFRSF11B TNFSF11
178 saethre-chotzen syndrome 10.4 ALPP BGLAP FGFR3 RUNX2
179 chiari malformation 10.4 DKK1 FGFR3
180 periostitis 10.4 ALPP TNFRSF11A
181 uremic neuropathy 10.4 B2M PTH
182 urinary system disease 10.4 B2M FGF23 PTH
183 dysplasia epiphysealis hemimelica 10.4 EXT1 EXT2
184 secondary hyperparathyroidism of renal origin 10.4 ACP5 BGLAP CALCA FGF23 PTH TNFRSF11B
185 exostosis 10.4 BGLAP EXT1 EXT2
186 breast adenocarcinoma 10.3 CALCA CTSK TNFSF11
187 osteochondroma 10.3 EXT1 EXT2 FGFR3
188 breast cancer 10.2
189 hereditary multiple osteochondromas 10.2 EXT1 EXT2
190 tick infestation 10.2 ALPL ALPP
191 prostate cancer 10.1
192 prostate cancer, hereditary, 8 10.1
193 prostate cancer, hereditary, 6 10.1
194 multiple enchondromatosis, maffucci type 10.1 EXT1 EXT2
195 cystic fibrosis 10.1
196 primary biliary cholangitis 10.1
197 biliary cirrhosis, primary, 1 10.1
198 primary biliary cirrhosis 10.1
199 thalassemia 10.0
200 overnutrition 10.0
201 gaucher's disease 10.0
202 arthritis 10.0
203 human immunodeficiency virus infectious disease 10.0
204 liver disease 9.9
205 secondary hyperparathyroidism 9.9
206 mammary paget's disease 9.9
207 leukemia 9.9
208 inflammatory bowel disease 9.9
209 renal tubular acidosis 9.9
210 beta-thalassemia 9.9
211 cholestasis 9.9
212 adenoma 9.9
213 bone mineral density quantitative trait locus 8 9.8
214 bone mineral density quantitative trait locus 15 9.8
215 nephrolithiasis 9.8
216 lung cancer 9.8
217 celiac disease 1 9.8
218 crohn's disease 9.8
219 lymphocytic leukemia 9.8
220 aging 9.7
221 nephrotic syndrome 9.7
222 cholangitis 9.7
223 autoimmune progesterone dermatitis 9.7
224 leukemia, chronic lymphocytic 2 9.7
225 leukemia, chronic lymphocytic 9.7
226 cholangitis, primary sclerosing 9.7
227 polyglucosan body myopathy 1 with or without immunodeficiency 9.7
228 bronchopulmonary dysplasia 9.7
229 diabetes mellitus 9.7
230 osteoarthritis 9.7
231 cystinosis 9.7
232 sarcoma 9.7
233 osteopoikilosis 9.7
234 nephrocalcinosis 9.7
235 obstructive jaundice 9.7
236 sclerosing cholangitis 9.7
237 epilepsy 9.7
238 kidney cancer 9.7
239 pseudohypoparathyroidism 9.7
240 myopathy 9.7
241 amyloidosis 9.7
242 leukemia, b-cell, chronic 9.7
243 systemic lupus erythematosus 9.6
244 cystinosis, nephropathic 9.6
245 myelofibrosis 9.6
246 sjogren syndrome 9.6
247 graves disease 1 9.6
248 hypophosphatemic rickets, x-linked dominant 9.6
249 sickle cell anemia 9.6
250 anorexia nervosa 9.6
251 anxiety 9.6
252 hepatitis c virus 9.6
253 leptin deficiency or dysfunction 9.6
254 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.6
255 mucopolysaccharidosis-plus syndrome 9.6
256 acute leukemia 9.6
257 alcohol abuse 9.6
258 hematopoietic stem cell transplantation 9.6
259 hepatitis 9.6
260 liver cirrhosis 9.6
261 metabolic acidosis 9.6
262 heart disease 9.6
263 hemosiderosis 9.6
264 patulous eustachian tube 9.6
265 dementia 9.6
266 biliary atresia 9.6
267 sapho syndrome 9.6
268 frozen shoulder 9.6
269 hepatitis c 9.6
270 acromegaly 9.6
271 bursitis 9.6
272 primary hyperoxaluria 9.6
273 pancreatitis 9.6
274 hyperthyroidism 9.6
275 irritable bowel syndrome 9.6
276 dwarfism 9.6
277 renal tubular acidosis, distal 9.6
278 depression 9.6
279 hypoxia 9.6
280 myotonia 9.6
281 encephalopathy 9.6
282 osteoporotic fracture 9.6
283 bladder cancer 9.6
284 cleft palate, isolated 9.6
285 chronic recurrent multifocal osteomyelitis 9.6
286 degenerative disc disease 9.6
287 klippel-feil syndrome 9.6
288 blount's disease 9.6
289 neuropathy - hereditary 9.6
290 dysautonomia 9.6
291 arthropathy, progressive pseudorheumatoid, of childhood 9.5
292 complement component 3 deficiency, autosomal recessive 9.5
293 muscle disorders 9.5
294 conn's syndrome 9.5
295 gout 9.5
296 histiocytosis 9.5
297 complement component 3 deficiency 9.5
298 myeloid sarcoma 9.5
299 rosai-dorfman disease 9.5
300 achondroplasia 9.4
301 arteries, anomalies of 9.4
302 caffey disease 9.4
303 hepatocellular carcinoma 9.4
304 cherubism 9.4
305 factor viii deficiency 9.4
306 fish-eye disease 9.4
307 hypochondroplasia 9.4
308 neurofibromatosis, type i 9.4
309 neurofibromatosis, type iv, of riccardi 9.4
310 nevus, epidermal 9.4
311 gnathodiaphyseal dysplasia 9.4
312 nephrolithiasis, calcium oxalate 9.4
313 pheochromocytoma 9.4
314 mccune-albright syndrome 9.4
315 polyposis, gastric 9.4
316 hutchinson-gilford progeria syndrome 9.4
317 sarcoidosis 1 9.4
318 scleroderma, familial progressive 9.4
319 scoliosis, isolated 1 9.4
320 small cell cancer of the lung 9.4
321 alkaptonuria 9.4
322 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 9.4
323 indifference to pain, congenital, autosomal recessive 9.4
324 osteoporosis-pseudoglioma syndrome 9.4
325 pseudoxanthoma elasticum 9.4
326 pycnodysostosis 9.4
327 rothmund-thomson syndrome 9.4
328 insulin-like growth factor i 9.4
329 hypophosphatemic rickets, x-linked recessive 9.4
330 focal dermal hypoplasia 9.4
331 hemophilia a 9.4
332 asthma 9.4
333 dermatitis herpetiformis, familial 9.4
334 stuve-wiedemann syndrome 9.4
335 yemenite deaf-blind hypopigmentation syndrome 9.4
336 bone mineral density quantitative trait locus 3 9.4
337 scheie syndrome 9.4
338 psoriatic arthritis 9.4
339 parathyroid carcinoma 9.4
340 choanal atresia, posterior 9.4
341 osteogenesis imperfecta, type vii 9.4
342 ewing sarcoma 9.4
343 microvascular complications of diabetes 3 9.4
344 microvascular complications of diabetes 4 9.4
345 microvascular complications of diabetes 6 9.4
346 microvascular complications of diabetes 7 9.4
347 leukemia, acute lymphoblastic 9.4
348 gastric cancer 9.4
349 osteogenesis imperfecta, type vi 9.4
350 graft-versus-host disease 9.4
351 nevus comedonicus 9.4
352 pulmonary hypertension 9.4
353 alcoholic liver cirrhosis 9.4
354 brain injury 9.4
355 joint disorders 9.4
356 pseudoarthrosis 9.4
357 severe combined immunodeficiency 9.4
358 thrombocytopenia 9.4
359 autosomal dominant disease 9.4
360 paraganglioma 9.4
361 peripheral artery disease 9.4
362 sleep apnea 9.4
363 adrenal gland pheochromocytoma 9.4
364 lymphoma 9.4
365 colitis 9.4
366 crohn's colitis 9.4
367 scoliosis 9.4
368 idiopathic scoliosis 9.4
369 progressive familial intrahepatic cholestasis 9.4
370 fanconi syndrome 9.4
371 lipoid nephrosis 9.4
372 spondyloarthropathy 9.4
373 chondrocalcinosis 9.4
374 gestational diabetes 9.4
375 cryptococcosis 9.4
376 otosclerosis 9.4
377 tuberous sclerosis 9.4
378 cystic echinococcosis 9.4
379 echinococcosis 9.4
380 neuroendocrine tumor 9.4
381 richter's syndrome 9.4
382 bone cancer 9.4
383 impotence 9.4
384 hypogonadism 9.4
385 dysostosis 9.4
386 arteriosclerosis 9.4
387 dermatitis 9.4
388 hairy cell leukemia 9.4
389 skin carcinoma 9.4
390 mastocytosis 9.4
391 plasmacytoma 9.4
392 syphilis 9.4
393 combined t cell and b cell immunodeficiency 9.4
394 acquired immunodeficiency syndrome 9.4
395 connective tissue disease 9.4
396 diffuse idiopathic skeletal hyperostosis 9.4
397 hypogonadotropism 9.4
398 retinal degeneration 9.4
399 lung disease 9.4
400 dermatitis herpetiformis 9.4
401 eating disorder 9.4
402 lupus erythematosus 9.4
403 psoriasis 9.4
404 macroglobulinemia 9.4
405 sickle cell disease 9.4
406 al amyloidosis 9.4
407 aminoaciduria 9.4
408 bone marrow necrosis 9.4
409 chronic graft versus host disease 9.4
410 degos 'en cocarde' erythrokeratoderma 9.4
411 germ cells tumors 9.4
412 lathyrism 9.4
413 lymphangiomatosis 9.4
414 medullary sponge kidney 9.4
415 slipped capital femoral epiphysis 9.4
416 hereditary hypophosphatemic rickets 9.4
417 mucopolysaccharidoses 9.4
418 phalangeal microgeodic syndrome 9.4
419 epiphysiolysis of the hip 9.4
420 eosinophilic granuloma 9.4

Graphical network of the top 20 diseases related to Bone Disease:



Diseases related to Bone Disease

Symptoms & Phenotypes for Bone Disease

UMLS symptoms related to Bone Disease:


back pain, bone pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Disease:

47 (showing 13, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ALPL B2M CTSK DKK1 EXT1 FGFR3
2 growth/size/body region MP:0005378 10.3 ALPL B2M CTSK DKK1 EXT1 FGF23
3 craniofacial MP:0005382 10.25 ALPL CTSK DKK1 EXT1 FGFR3 PTH
4 homeostasis/metabolism MP:0005376 10.18 ALPL B2M CTSK DKK1 FGF23 FGFR3
5 hematopoietic system MP:0005397 10.17 ALPL B2M CTSK FGF23 FGFR3 PTH
6 digestive/alimentary MP:0005381 10.15 ALPL B2M CTSK EXT1 FGF23 FGFR3
7 endocrine/exocrine gland MP:0005379 10.13 ALPL B2M CTSK FGF23 PTH RUNX2
8 immune system MP:0005387 10.11 ALPL B2M CTSK FGF23 FGFR3 PTH
9 limbs/digits/tail MP:0005371 10.07 ALPL CTSK DKK1 EXT1 FGF23 FGFR3
10 mortality/aging MP:0010768 9.97 ALPL B2M DKK1 EXT1 EXT2 FGF23
11 integument MP:0010771 9.92 B2M EXT1 FGF23 FGFR3 RUNX2 TNFRSF11A
12 respiratory system MP:0005388 9.56 ALPL CTSK DKK1 FGF23 FGFR3 RUNX2
13 skeleton MP:0005390 9.47 ALPL CTSK DKK1 EXT1 EXT2 FGF23

Drugs & Therapeutics for Bone Disease

Drugs for Bone Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 1081, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
AT-101 Approved, Investigational Phase 4,Phase 3 90141-22-3, 652-67-5 12597
2
Nitric Oxide Approved Phase 4,Phase 3 10102-43-9 145068
3
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3 87-33-2 6883
4
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
5
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
6
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9002-64-6
7
Emtricitabine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
8
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 147127-20-6 464205
9
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 471-34-1
10
Alendronate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66376-36-1, 121268-17-5 2088
11
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
12
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113775-47-6 5311068 68602
13
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
14
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
15
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
16
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
17
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
18
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-83-0 5994
19
Etidronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7414-83-7, 2809-21-4 3305
20
Risedronate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 105462-24-6 5245
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 2921-57-5
23
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-24-8 5755
24
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 302-25-0
25
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
26
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
27
Thrombin Approved, Investigational Phase 4
28
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
29
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
30
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52232-67-4 16133850
31
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 615258-40-7
32
Pioglitazone Approved, Investigational Phase 4,Not Applicable 111025-46-8 4829
33
Linagliptin Approved Phase 4 668270-12-0 10096344
34
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 6400441 383414
35
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
36
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
37
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
38
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
39
Etanercept Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 185243-69-0
40
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 599-79-1 5359476 5353980
41
Adalimumab Approved Phase 4,Phase 3,Phase 2,Not Applicable 331731-18-1 16219006
42
Mecasermin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68562-41-4
43
Pamidronate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 40391-99-9 4674
44
Rifampicin Approved Phase 4,Phase 3,Early Phase 1 13292-46-1 5381226 5458213
45
Pyrazinamide Approved, Investigational Phase 4,Early Phase 1 98-96-4 1046
46
Ethambutol Approved Phase 4 74-55-5 14052 3279
47
Isoniazid Approved, Investigational Phase 4,Phase 3,Early Phase 1 54-85-3 3767
48
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
49
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
50
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
51
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
52
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-03-3
53
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
54
Cinacalcet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 226256-56-0 156419
55
Triamcinolone Approved, Vet_approved Phase 4,Early Phase 1,Not Applicable 124-94-7 31307
56
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6
57
Remifentanil Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 132875-61-7 60815
58
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
59
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 2078-54-8 4943
60
Methamphetamine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 537-46-2 10836
61
Bupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 38396-39-3, 2180-92-9 2474
62
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 84057-95-4 175805 71273
63
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-22-0, 481-30-1 10204 6013
64
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
65
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
66
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0